Physician profile
Andre B Spindler
NPI 1306904339
$2,535.72
in general payments reported to CMS, 2019-2025
22 companies · $70.98 in 2025
The $70.98 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $425 · 2021: $586 · 2022: $423 · 2023: $202 · 2024: $460 · 2025: $70.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $814.26 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $278.81 | 2019-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.05 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $142.27 | 2019-2024 | Zepbound |
| Pfizer INC. | $135.28 | 2022-2025 | |
| Novo Nordisk INC | $114.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $89.34 | 2022-2024 | Airsupra |
| Abbvie INC. | $87.15 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $84.51 | 2024 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.70 | 2019-2021 | |
| Amgen INC. | $71.65 | 2020-2024 | Repatha |
| Arbor Pharmaceuticals, INC. | $61.72 | 2019-2021 | |
| Glaxosmithkline, LLC. | $56.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.13 | 2020-2021 | |
| Daiichi Sankyo INC. | $44.74 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $42.49 | 2023-2024 | Edarbi, Edarbi |
| Althera Pharmaceuticals LLC | $38.71 | 2021 | |
| Esperion Therapeutics, INC. | $35.86 | 2021 | |
| Boston Scientific Corporation | $29.04 | 2019 | |
| Gilead Sciences, INC. | $25.02 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.78 | 2019 | |
| Amarin Pharma, INC. | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Spindler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.